Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Weight-Loss drug UBT251 enters Mid-Stage trial

NCT ID NCT07395687

Recruiting now Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether UBT251 is safe and effective for people who are overweight or have obesity. About 333 participants will receive either UBT251 or a placebo injection. The main goals are to check for side effects and measure weight change over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
UBT251
What this could lead to
If it works, this could lead to a new weight-loss medication that helps people with overweight or obesity lose weight safely.
What could go wrong
This is an early Phase 2 trial, so the drug may not prove effective or could have side effects. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Altasciences Clinical Company, Inc

    RECRUITING

    Montreal, Quebec, H3P 3P1, Canada

  • Altasciences Clinical Kansas, Inc.

    RECRUITING

    Overland Park, Kansas, 66212, United States

  • Altasciences Clinical LA, Inc.

    RECRUITING

    Cypress, California, 90630, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.